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Distribution of Chromosomal Abnormalities Commonly
Observed in Adult Acute Myeloid Leukemia in Pakistan as
Predictors of Prognosis
Muhammad Shariq Shaikh1*, Zeeshan Ansar Ahmed1, Mohammad Usman
Shaikh1, Salman Naseem Adil1, Mohammad Khurshid2, Tariq Moatter1, Anila
Rashid1, Farheen Karim1, Ahmed Raheem1, Natasha Ali1
Abstract
Objectives: The heterogenous response to treatment in acute myeloid leukemia (AML) can be attributed largely to
the difference in cytogenetic features identified in between cases. Cytogenetic analysis in acute leukemia is now
routinely used to assist patient management, particularly in terms of diagnosis, disease monitoring, prognosis and risk
stratification. Knowing about cytogenetic profile at the time of diagnosis is important in order to take critical decisions
in management of these patients. The study was conducted to determine the distribution of cytogenetic abnormalities in
Pakistani adult patients with AML in order to have insights regarding behavior of the disease. Methods: A retrospective
analysis of all the cases of AML (≥15years old) diagnosed at Aga Khan University from January 2011 to December 2016
was performed. Cytogenetic analysis was made for all cases using the trypsin-Giemsa banding technique. Karyotypes
were interpreted using the International System for Human Cytogenetic Nomenclature (ISCN) criteria. Results:
A total of 321 patients were diagnosed with AML during the study period, of which 288 samples successfully yielded
metaphase chromosomes. The male to female ratio was 1.7:1. A normal karyotype was present in 61% (n=176) of
the cases whereas, 39% (n=112) had an abnormal karyotype. Of the abnormal cases, t (8;21) (q22;q22) and t (15;17)
(q22;q12) were identified in 8.3% and 4.9% cases respectively. Adverse prognostic cytogenetic subgroups including
complex karyotype, monosomy 7 and t(6;9)(p23;q34) were identified in 9%, 1% and 0.7% patients respectively.
Conclusions: This largest cytogenetic data in adult AML from Pakistan showed comparable prevalence of favorable
prognostic karyotype to international data. The prevalence of specific adverse prognostic karyotype was low.
Keywords: AML- cytogenetics- G-banding- metaphase- adult- Pakistan
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Introduction
Acute myeloid leukemia (AML) is a malignant
disorder characterized by clonal expansion
and accumulation of precursor myeloid cells with
a reduced capacity to differentiate into more mature
cellular elements. It can occur at all ages but has its peak
incidence in the seventh decade. The heterogeneity of
AML in terms of morphology, immunological phenotype,
cytogenetic and molecular abnormalities is reflected in
substantially different response to treatment between
cases.
Treatment related mortality and resistance to standard
chemotherapy are the two chief determinants of risks in
AML (Estey, 2013). Diagnostic karyotype in AML predicts
disease resistance and allows risk-stratified treatment
approaches to be followed. Comprising of 11% of all cases,

“AML with recurrent genetic abnormalities” is a separate
entity recognized by 2008 World Health Organization
(WHO) classification (Vardiman et al., 2009). This
definition has been retained in updated 2016 classification
as well (Arber et al., 2016). It is the most influential
independent prognostic factors in terms of treatment
outcomes (Grimwade and Hills, 2009).
Amongst various familiar cytogenetic abnormalities
in AML, t (15;17) (q22;q12) in patients with acute
promyelocytic leukemia (APL), t (8;21) (q22;q22)
and inv (16) (p13q22)/t (16;16) (p13;q22) have been
consistently found associated with better outcomes.
Cure rates up to 60-70% have been documented in
several assessments (Zhu et al., 2013). Conversely,
abnormalities of 3q (abn(3q)), deletions of 5q (del(5q)),
monosomies of chromosome 5 and/or 7 (-5/-7), t (9;22) or
complex karyotype (more than three unrelated changes) are

Section of Hematology and Transfusion Medicine, Department of Pathology and Laboratory Medicine, 2Department of Oncology,
Aga Khan University Hospital, Stadium Road, 74800, Karachi, Pakistan.*For Correspondence: muhammad.shariq@aku.edu
1

Asian Pacific Journal of Cancer Prevention, Vol 19

1903

Muhammad Shariq Shaikh et al

associated with very poor prognoses. In fact, monosomal
karyotype invariably portents resistant disease even after
allogeneic bone marrow transplant (Kayser et al., 2012).
The prognosis of normal karyotype, the commonest
cytogenetic feature in AML, is highly variable ranging
from cure to highly refractory disease. The influence of
underlying mutations on outcome of such cases is well
known (Schlenk et al., 2008).
The cytogenetic data of Pakistani adults with AML is
scarce. Literature review retrieved a couple of small studies
addressing the cytogenetic profile of Pakistani AML
patients (Harani et al., 2006; Aziz and Qureshi, 2008).
The current study aimed in determining the distribution of
chromosomal abnormalities in Pakistani adult patients
with AML in order to have an insight about the behavior of
this condition.

were included for analysis and results were expressed as
frequencies and percentages. Categorical variables were
compared by the use of the Chi-square test or Fisher Exact
test. Significance of mean age between two groups was
calculated by Independent-Samples T-Test. A p-value of
<0.05 was taken as significant.

Materials and Methods

Results

Study area and subjects
This was a cross-sectional analysis performed at Aga
Khan University Hospital in the Sections of Hematology
and Molecular Pathology. Using non-probability
consecutive sampling technique, all patients diagnosed
as AML who were ≥15 years of age from January 2011
to December 2016 were included in the analysis. Cases
which didn’t yield metaphase chromosome were excluded
from the analysis.

A total of 321 adults were diagnosed with AML during
the study period. There were 201 males and 120 females
(M:F=1.7:1). Thirty-three (10%) cases didn’t yield
metaphase chromosomes and were excluded from the
analysis. Of successful 288 cases with cytogenetic results,
a normal karyotype was identified in 176 (61.1%) patients
and abnormal karyotype in 112 (38.9%) patients (Table 1).
The most prevalent favorable chromosomal abnormality
was t (8;21) (q22;q22), which was present in 24 (8.3%) of
288 patients. Translocation (15;17) (q22:q12) occurred in
14 (4.9%) and inv(16)(p13q22) was present in 2 (0.7%)
patients. Poor cytogenetic abnormalities including t(6;9)
(p23;q34), trisomy 8, monosomy 7 and complex karyotype
collectively were identified in 38 (13.2%) patients
(Table 1). Thirty four (11.8%) patients had miscellaneous
chromosomal abnormalities including deletions, additions,
inversions, other translocations and marker chromosomes.
Forty-two percent (n=122) patients were under 30 years of
age however, prevalence of favorable or unfavorable

Diagnosis
In all cases, the diagnosis of AML was confirmed
by morphology and appropriate cytochemical staining.
Immunophenotyping by either flow cytometry or
immunohistochemistry was performed where possible by
the use of standard methodologies.
Cytogenetic analysis
Analysis was performed on pretreatment bone marrow
samples by the use of conventional G-banding techniques.
Bone marrow samples were cultured using standard
culture techniques followed by harvesting (incubation,
centrifugation and addition of hypotonic solution). After
addition of fixative (3:1 methanol to glacial acetic acid)
and trypsin treatment, Giemsa staining was performed.
Slides were examined under microscope and at least 20
mitosis were analyzed whenever possible.
Cytogenetic abnormalities
Chromosomal abnormalities were identified and
described according to the International System for Human
Cytogenetic Nomenclature (ISCN 2009, 2013, 2016).
Cytogenetic abnormalities were classified into balanced,
unbalanced and complex abnormalities. Complex
karyotype was defined as presence of three or more clonal
chromosomal abnormalities in the absence of established
chromosomal abnormalities. Based on WHO 2016 update,
three cytogenetic risk groups were defined as favorable,
intermediate and unfavorable (Arber et al., 2016).
Data analysis
Age, gender and types of cytogenetic abnormalities
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Ethical issues
An ethical exemption to conduct this analysis
was granted by the institutional ethical review
board (3569-Pat-ERC-15). Written and informed
consent was taken from all patients as per institutional
policy before collecting bone marrow samples. Relevant
counseling regarding prognostic impact of the detected
abnormality was provided to all who followed up in
outpatient department or in the wards during admissions.

Table 1. Karyotypic Features of 288 Patients with AML
Karyotype

n (%)

Normal

176 (61.1)

Abnormal

112 (38.9)

Balanced

50 (17.4)

t (8;21) (q22;q22.1)

24 (8.3)

t (15;17) (q22;q12)

14 (4.9)

inv (16) (p13.1q22)

2 (0.7)

t (6;9) (p23;q34.1)

2 (0.7)

Others

8 (2.8)

Unbalanced
Trisomy 8
Monosomy 7
Others
Complexƚ

36 (12.5)
7 (2.4)
3 (1)
26 (9.0)
26 (9)

Numbers and percentages presented are out of total cases with
successful cytogenetic results; †Three or more clonal chromosomal
abnormalities in the absence of aforementioned established
chromosomal abnormalities
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Table 2. Age Wise Distribution of Karyotype in Various Prognostic Groups
Prognostic Significance n (%)
Age in Years

Favorable

Intermediate

Unfavorable

Total

15-30

23 (18.9)

81 (66.4)

18 (14.8)

122 (42.4)

31-45

11 (13.9)

61 (77.2)

7 (8.9)

79 (27.4)

6 (6.9)

74 (85.1)

7 (8)

87 (30.2)

40 (13.9)

216 (75)

32 (11.1)

288 (100)

>45
Total n (%)

cytogenetic abnormalities was not significantly different
in the various age groups (p=0.3) (Table 2).

Discussion
The prognosis in AML depends on both
the clinical and cytogenetic/molecular features
(Yunus et al., 2015; Zehra et al., 2016). Clinical features
that predict the likelihood of achieving a complete
remission and subsequent disease-free survival include:
younger age, good performance status, absence of prior
hematological disorder like myelodysplastic syndrome
or myeloproliferative neoplasms, exposure to radiation
or cytotoxic agents and other medical co-morbidities
(Su et al., 2013). Karyotype is one of the main
determinants of prognosis in AML and all patients must
undergo cytogenetic analysis at the time of diagnosis.
The updated 2016 WHO classification of hematological
malignancies, continues to define AML by focusing on
significant cytogenetic and molecular genetic subgroups.
To the best of our knowledge, we have reported the largest
cytogenetic data in Pakistani adults with AML.
Acute myeloid leukemia is around twice as common
in males than females. Gender distribution in our analysis
was comparable with published western data with
a significantly higher proportion of males (p=0.007).
The distribution of favorable and unfavorable cytogenetic
abnormalities with respect to the gender was not
significantly different (p=0.2).
Translocation (8;21)(q22;q22) and t(15;17)(q22:q12)
constituted the only recurring abnormalities with
a frequency above 3%. Both these abnormalities comprise
5-8% of AML (Byrd et al., 2002; Su et al., 2014).
In our study, the former occurred at a frequency of 8.1%
whereas the later at 4.9%. Other specific abnormalities
such as t (6;9) (p23;q34) and inv (16) (p13q22) were seen
less frequently. The cumulative prevalence of favorable
cytogenetic abnormalities (13.9%) including t (8;21)
(q22;q22), t (15;17) (q22;q12) and inv(16) (p13q22)
was not significantly higher in the different age groups
(p=0.3) (Table 2).
Complex karyotype emerged as the predominant
unfavorable cytogenetic risk group in this study.
The prevalence of monosomy 7, the only specific
unfavorable abnormality in our study was very low
(1%); the two large studies reported a frequency of
around 7% (Byrd et al., 2002; Grimwade et al., 2010).
Other unfavorable cytogenetic abnormalities including
3q (abn(3q)), deletions of 5q (del(5q)), monosomy 5 and
t (9;22) were not identified in this analysis. Several other
single chromosomal abnormalities were also identified but

were too infrequent to be analyzed separately.
Besides being the largest cytogenetic data in Pakistani
adults with AML, other strength of this study is use
of conventional cytogenetic method for karyotype
determination. Conventional cytogenetic provides
status of all chromosomes and hence, it identifies
all the changes present in a karyotype. Nonetheless,
a fraction of cases are liable to omission due to its
inherent low sensitivity. More sophisticated methods
like fluorescence in situ hybridization (FISH) and
polymerase chain reaction (PCR) have higher yields
but target only specific lesion in question and therefore,
information about other possible findings is not provided.
Next-Generation Sequencing (NGS) technology has
made a huge impact on prognostication and clinical
diagnostics. It has expanded genes that cause malignancies
and will soon replace the routine testing for single gene
mutation. This will play a significant role in personalized
medicine. The 2016 WHO update emphasizes significant
impact of AML biomarkers on patient outcome.
Next-Generation Sequencing will serve as a powerful
tool for gaining deeper insights into leukemia stem cell
phenotype, signaling pathways and function. This will
provide the basis for more comprehensive knowledge of
data bank that can serve as a valuable tool to advance
individualized treatment approaches including more
accurate assessment of minimal residual disease in AML.
In conclusion, this study showed recurrent cytogenetic
abnormalities in 14.6% Pakistani adults with AML.
Favorable karyotypes, t(8;21)(q22;q22) followed by
t (15;17) (q22:q12) were identified as the most prevalent
specific chromosomal abnormalities; the cumulative
prevalence however was not significantly different in
various age groups. The complex karyotype constituted
the predominant unfavorable karyotype.
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